Scientists have shown how stomach cancers can dodge the effects of a promising new experimental treatment – raising the possibility of outsmarting cancer by predicting drug resistance in advance.

TP53, a central gene to DNA damage repair (DDR), is mutated in 50% of gastric/GEJ cancer pts. Pre-clinical models from multiple cancer types demonstrate that cancer cells with TP53 mutations rely on ...

Clinicians can help reduce gastric cancer incidence and mortality in high-risk groups through endoscopic screening and surveillance of precancerous conditions, such as gastric intestinal ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting ...

Gastric cancer is the fourth leading cause of cancer-related deaths worldwide. Infection with Helicobacter pylori bacteria, whilst asymptomatic for most people, has long been identified as the ...

The clinical trial and a new study mark a significant leap in the fight against gastric cancer with peritoneal spread. Read more at straitstimes.com. Read more at straitstimes.com.

East Asian people are more likely to develop a more aggressive type of stomach cancer because of their higher likelihood of alcohol intolerance, according to a new study led by researchers in Japan.

The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's website showed on Friday.

Zolbetuximab binds claudin 18.2 and triggers immune responses that kill the cancer cells. The FDA approval was based on two international phase 3 trials — SPOTLIGHT and GLOW .